Activation of CAR has been associated with both beneficial effects, such as mitigating hepatic steatosis, and adverse outcomes, such as exacerbating hepatic fibrosis and hepatocarcinogenesis, depending on the experimental context [18,19]. The gene discussed is NR1I3; the disease is fatty liver disease.